SOUTH SAN FRANCISCO, CA, Jun 12, 2026 – Synlico Inc., a Patient-Native Causal AI biotech, today announced it has been selected as a BioPharma Honorable Mention in the Nebius AI Discovery Awards 2026. The competition received 646 applicants across all award categories. This recognition places Synlico among the top 10 companies in its category and underscores the transformative potential of its platform, SynCausalTM.
SynCausalTM is a patient-native generative causal discovery and inference platform that learns directed gene–gene causal graphs from large-scale primary patient single-cell data. At the center of SynCausalTM is a generative causal AI model that learns patient-context directed causal gene regulatory graphs, and executes do(X)-style virtual interventions directly in human disease context. SynCausalTM identifies upstream disease drivers, quantifies downstream effects of gene and pathway interventions, and returns predicted intervention effects with mechanistic rationales.
“As drug discovery shifts from black-box prediction to quantitative functional cell models and predictive biology, Synlico tackles a core bottleneck: drug R&D decisions and human disease biology remain correlation-led and often fail to translate across heterogeneous patients and microenvironments,” said Dr. Jingwei Lu, Founder and Chief Executive Officer of Synlico Inc. “Recognition from the Nebius AI Discovery Awards validates the urgency of this approach and the strength of what we’re building.”
Synlico’s competitive advantage is compounded by one of the largest causal-grade patient data infrastructures in the field: over 200 million single cells from approximately 36,000 primary patient samples spanning 700+ disease indications.
About Synlico
Synlico is a patient-native causal AI biotech building a generative causal discovery and inference platform SynCausalTM that learns directed gene causal graphs from primary patient scRNA-seq at scale. As drug discovery shifts from black-box prediction to quantitative functional cell models and predictive biology, Synlico tackles a core bottleneck: drug R&D decisions and human disease biology remain correlation-led and often fail to translate across heterogeneous patients and microenvironments. Synlico is a resident of Johnson & Johnson’s global incubator networks, JLABS. For more information, visit www.synlico.com.
Synlico Contact
Linda Guo
info@synlico.com
